SCHEMBL3049283

SCHEMBL3049283

CN1CCC(N(C)C(=O)COc2cccc(Cl)c2Cl)CC1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.65
SIGMAR1 Q99720 3/20 0.64
NPSR1 Q6W5P4 2/20 0.49
LMNA P02545 1/20 0.49
HTR1D P28221 2/20 0.47
HTR1B P28222 2/20 0.47
NPC1 O15118 2/20 0.47
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 2/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 1/20 0.44
CCR5 P51681 1/20 0.43
SSTR1 P30872 1/20 0.43
SSTR4 P31391 1/20 0.43
GHSR Q92847 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4340461 0.92 POLB (0.57) POLBSIGMAR1NPSR1LMNAHTR1D
SCHEMBL3050521 0.91 POLB (0.71) POLBSIGMAR1NPSR1LMNANPC1
SCHEMBL3055296 0.82 POLB (0.67) POLBSIGMAR1NPSR1LMNANPC1
SCHEMBL3051897 0.82 POLB (0.73) POLBKMT2AALDH1A1GAAL3MBTL1
SCHEMBL3042587 0.81 POLB (0.69) POLBNPSR1LMNAKMT2AALDH1A1
SCHEMBL3047625 0.80 POLB (0.70) POLBNPSR1LMNANPC1KMT2A
SCHEMBL8762876 0.78 SIGMAR1 (1.00) SIGMAR1
SCHEMBL8762950 0.78 SIGMAR1 (1.00) SIGMAR1
SCHEMBL8762880 0.78 SIGMAR1 (1.00) SIGMAR1
Hydrochloric Acid SCHEMBL10617583 0.77 SIGMAR1 (0.98) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1434765-B1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR HIGH POINT PHARMACEUTICALS LLC (US) 2009-12-02 EP claimed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
EP-1434765-B1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR HIGH POINT PHARMACEUTICALS LLC (US) 2009-12-02 EP disclosed
EP-1434765-B1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR HIGH POINT PHARMACEUTICALS LLC (US) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222386-A1 SUBSTITUTED PIPERIDINES HRH3, HRH4, HRH2 POLB 3476/4885SIGMAR1 142/4885NPSR1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.